

8. **(Twice amended)** An isolated proteinic or glycoprotein inhibitor of xylanase comprising an amino acid sequence at least 70% homologous to SEQ ID NO:1 or SEQ ID NO:2.

9. **(Twice amended)** The isolated inhibitor of claim 8, wherein the amino acid sequence is the N-terminal amino acid sequence of the protein or glycoprotein.

10. **(Twice amended)** The isolated inhibitor of claim 8 comprising an amino acid sequence at least 85% homologous to SEQ ID NO:1 or SEQ ID NO:2.

C' incl.
11. **(Twice amended)** The isolated inhibitor of claim 10, wherein the amino acid sequence is the N-terminal amino acid sequence of the protein or glycoprotein.

12. **(Twice amended)** The isolated inhibitor of claim 7, comprising SEQ ID NO:1 or SEQ ID NO:2.

13. **(Twice amended)** The isolated inhibitor of claim 12, wherein SEQ ID NO:1 or SEQ ID NO:2 is the N-terminal amino acid sequence of the protein or glycoprotein.

REMARKS

Claims 6-13 have been amended to provide that the claimed inhibitor is an isolated inhibitor. Support for the amendments to the claims is found in the specification as filed.

I. Rejection under 35 U.S.C. § 101

The Examiner has rejected claims 6-13 under 35 U.S.C. § 101 on the assertion that the claims are directed towards non-statutory subject matter. Applicants have amended Claims 6 and 8 to recite "An isolated proteinic or glycoprotein inhibitor of xylanase..." and Claims 7 and 9 to 13 have been amended to recite the "isolated inhibitor of claim..." Applicants respectfully submit that amended Claims 6 to 13 are directed towards statutory subject matter and respectfully request withdrawal of the rejection to Claims 6-13 under 35 U.S.C. § 101.

II. Rejections Based on the Assertion that the Specification Does Not Satisfy the Written Description Requirement

The Examiner has rejected Claims 6 to 13 under 35 U.S.C. § 112, first paragraph on the assertion that the specification does not describe a sufficient number of species